A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
- Authors
- Park, Min Ho; Lee, Soo Jung; Noh, Woo Chul; Jeon, Chang Wan; Lee, Seok Won; Son, Gil Soo; Moon, Byung-In; Lee, Jin Sun; Kang, Sung Soo; Suh, Young Jin; Gwak, Geumhee; Kim, Tae Hyun; Yoo, Young Bum; Kim, Hyun-Ah; Kim, Min Young; Kim, Ju Yeon; Jeong, Joon
- Issue Date
- Dec-2020
- Publisher
- Churchill Livingstone
- Keywords
- Eribulin mesylate; Breast cancer; Retrospective study; Korean patients
- Citation
- Breast, v.54, pp 121 - 126
- Pages
- 6
- Indexed
- SCIE
SCOPUS
- Journal Title
- Breast
- Volume
- 54
- Start Page
- 121
- End Page
- 126
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/49208
- DOI
- 10.1016/j.breast.2020.09.004
- ISSN
- 0960-9776
1532-3080
- Abstract
- Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study.
Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m(2) (equivalent to 1.4 mg/m(2) eribulin mesylate) by intravenous infusion for 2-5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs).
Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common.
Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified. (C) 2020 The Author(s). Published by Elsevier Ltd.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Breast and Endocrine Surgery > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.